engleski

The Effect Of Nadh (Enada) In Treatment Of Alzheimer's Disease

Aim. Considerable evidence exists of dopaminergic neurotransmitter system dysfunction and oxidative stress in pathogenesis of Alzheimer disease (AD>. Nicotinamide adenine dinucleotide (NADH) is biologically identified as a cofactor necessary for a number of cellular actions, such as energy production, cell regulation and DNA repair and repair of oxidative damage. The level of NADH is reduced in patients with neurodegenerative disorders. Clinical trials NADH has been shown to improve functioning in patients with Parkinson's disease and in chronic fatigue syndrome. The aim of the study was to establish weather NADH would improve cognitive functioning in patients with AD. Methods. This was randomized, double blind, placebo-controlled study which included 48 patients with mild to moderate AD. Primary outcome measure was the difference in Mattis Dementia Rating Scale total score between baseline and after six months of treatment. The rest of cognitive tests included Hopkins verbal learning test, for object memory test, Matching to sample test, Verbal fluency test, Clinical dementia rating scale and Mini Mental Status Scale Exam. Results. NADH subjects improved significantly compared to placebo group in verbal fluency test. Placebo group experienced decrease of verbal f1uency for 0.5 fewer words per minute and NADH group showed improvement of verbal fluency for 3.5 more words per minute (p=0.056). Six months after baseline a mean increase in MDRS Total score for NADH group was 2.8 (+/1.76) and for placebo group a mean decrease in MDRS Total score -4.9 (+/3.13) points (p=0.022). Conclusions. The results from this trial consistently demonstrate benefit of stabilized oral NADH on cognitive functioning in AD patients.

NADH; Alzheimer's disease; cognitive functions

nije evidentirano